Effect of obesity on high-density lipoprotein metabolism

Obesity

Volumn 15, Issue 12, 2007, Pages 2875-2888

  Rashid, Shirya ^a,b   Genest, Jacques ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Adiposity; Cardiovascular risk; Diet; Exercise; High density lipoproteins

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

EXERCISE; HUMAN; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW; WEIGHT REDUCTION;

ADIPOSITY; CHOLESTEROL, HDL; EXERCISE; HUMANS; LIPOPROTEINS, HDL; OBESITY; WEIGHT LOSS;

EID: 39149084382     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.342     Document Type: Review

References (129)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-14.
2. von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 1994;5:404-16.
3. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090-100.
4. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223-9.
5. Tilly-Kiesi M, Lichtenstein AH, Ordovas JM, et al. Subjects with ApoA-I(Lys107->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with All). Arterioscler Thromb Vase Biol. 1997;17:873-80.
6. Chroni A, Duka A, Kan HY, Liu T, Zannis VI. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry. 2005;44:14353-66.
7. Mott S, Yu L, Marcil M, Boucher B, Rondeau C, Genest J Jr. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. Atherosclerosis. 2000;152:457-68.
8. Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest. 1995;96:78-87.
9. Albrecht C, Baynes K, Sardini A, et al. Two novel missense mutations in ABCA1 result in altered trafficking and cause severe autosomal recessive HDL deficiency. Biochim Biophys Acta. 2004;1689:47-57.
10. Emmerich J, Verges B, Tauveron I, et al. Familial HDL deficiency due to marked hypercatabolism of normal apoA-I. Arterioscler Thromb. 1993;13:1299-306.
11. Williams PT, Haskell WL, Vranizan KM, Krauss RM. The associations of high-density lipoprotein subclasses with insulin and glucose levels, physical activity, resting heart rate, and regional adiposity in men with coronary artery disease: the Stanford Coronary Risk Intervention Project baseline survey. Metab Clin Exp. 1995;44:106-14.
12. Diehl AK, Fuller JH, Mattock MB, Salter AM, el Gohari R, Keen H. The relationship of high density lipoprotein subfractions to alcohol consumption, other lifestyle factors, and coronary heart disease. Atherosclerosis. 1988;69: 145-53.
13. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol. 2001;11:627-37.
14. Robins SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs Highdensity Lipoprotein Intervention Trial. Am J Cardiol. 2001; 88:19N-23N.
15. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arterioscler. 1990; 10:497-511.
16. Campfield LA, Smith FJ, Burn P. Strategies and potential molecular targets for obesity treatment. Science. 1998;280: 1383-7.
17. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-77.
18. Killeen J, Vanderburg D, Harlan WR. Application of weight-height ratios and body indices to juvenile populations - the National Health Examination Survey Data. J Chronic Dis. 1978;31:529-37.
19. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol. 2005;96:50K-8K.
20. Glueck CJ, Taylor HL, Jacobs D, Morrison JA, Beaglehole R, Williams OD. Plasma high density lipoprotein cholesterol: association with measurements of body mass. Circulation. 1980;62(Suppl IV):IV62-9.
21. Lamon-Fava S, Wilson PW, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1996;16:1509-15.
22. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjórntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984;288:1401-4.
23. Peiris AN, Sothmann MS, Hoffmann RG, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med. 1989; 110:867-72.
24. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metab Clin Exp. 1981;30:856-68.
25. Ostlund RE Jr, Staten M, Kohrt WM, Schultz J, Malley M. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. N Engl J Med. 1990;322:229-34.
26. Despres JP, Moorjani S, Ferland M, et al. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis. 1989;9: 203-10.
27. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54:254-60.
28. Nicklas BJ, Penninx BW, Ryan AS, Berman DM, Lynch NA, Dennis KE. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care. 2003;26:1413-20.
29. Despres JP, Couillard C, Gagnon J, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 2000;20:1932-8.
30. Lear SA, Toma M, Birmingham CL, Frohlich JJ. Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism. 2003;52:1295-301.
31. Schmitz G, Lackner KJ. High-density lipoproteins and atherosclerosis. Curr Opin Lipidol. 1993;4:392-400.
32. Dobiasova M, Frohlich J. Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL-cholesterol ratio. Physiol Res. 1998;47: 387-97.
33. Bertiere MC, Fumeron F, Rigaud D, Malon D, Apfelbaum M, Girard-Globa A. Low high density lipoprotein-2 concentrations in obese male subjects. Atherosclerosis. 1988; 73:57-61.
34. Carr MC, Hokanson JE, Zambon A, et al. The contribution of intra-abdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab. 2001;86:2831-7.
35. Miller NE. Associations of high-density lipoprotein sub-classes and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-97.
36. Patsch JR, Prasad S, Gotto AM Jr, Bengtsson-Olivecrona G. Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoproteins by hepatic lipase. J Clin Invest. 1984;74:2017-23.
37. Despres JP, Ferland M, Moorjani S, et al. Role of hepatic-triglyceride lipase activity in the association between intraabdominal fat and plasma HDL-cholesterol in obese women. Arteriosclerosis. 1989;9:485-92.
38. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sei USA. 1983;80:1449-53.
39. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-84.
40. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-8.
41. Coppack SW, Evans RD, Fisher RM, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metab Clin Exp. 1992;41:264-72.
42. Haemmerle G, Zimmermann R, Zechner R. Letting lipids go: hormone-sensitive lipase. Curr Opin Lipidol. 2003; 14: 289-97.
43. Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/ transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 1995;15:1819-28.
44. Arai T, Yamashita S, Hirano K, et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL-cholesterol levels in obesity. Arterioscler Thromb. 1994; 14:1129-36.
45. McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007;167:642-8.
46. Sorbris R, Petersson BG, Nilsson-Ehle P. Effects of weight reduction on plasma lipoproteins and adipose tissue metabolism in obese subjects. Eur J Clin Invest. 1981;11:491-8.
47. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006;48: 1782-90.
48. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537-52.
49. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vase Biol. 2002;22:667-73.
50. Foger B, Ritsch A, Doblinger A, Wessels H, Patsch JR. Relationship of plasma cholesteryl ester transfer protein to HDL-cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16:1430-6.
51. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest. 2003;33:1051-69.
52. Berenson A. End of trial is a big loss for Pfizer and heart patients. New York Times. 2006;4:A26.
53. Hamilton JA, Deckelbaum RJ. Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease? Nat Struct Mol Biol. 2007;14:95-7.
54. Howes LG, Kostner K. The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs. 2007; 16:1509-16.
55. Qiu X, Mistry A, Ammirati MJ, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007;14: 106-13.
56. Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res. 2005;46:896-903.
57. Paradis ME, Badellino KO, Rader DJ, et al. Visceral adiposity and endothelial lipase. J Clin Endocrinol Metab. 2006;91:3538-43.
58. Zimmermann R, Strauss JG, Haemmerle G, et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 2004;306:1383-6.
59. Schweiger M, Schreiber R, Haemmerle G, et al. Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. J Biol Chem. 2006;281:40236-41.
60. Langin D, Dicker A, Tavernier G, et al. Adipocyte lipases and defect of lipolysis in human obesity. Diabetes. 2005;54: 3190-7.
61. Jocken JW, Langin D, Smit E, et al. Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. J Clin Endocrinol Metab. 2007;92:2292-9.
62. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993;268:4032-6.
63. Marques-Vidal P, Jauhiainen M, Metso J, Ehnholm C. Transformation of high density lipoprotein 2 particles by hepatic lipase and phospholipid transfer protein. Atherosclerosis. 1997;133:87-95.
64. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, van ToI A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest. 1994;24:188-94.
65. Kaser S, Laimer M, Sandhofer A, Salzmann K, Ebenbichler CF, Patsch JR. Effects of weight loss on PLTP activity and HDL particle size. Int J Obes Relat Metab Disord. 2004;28:1280-2.
66. Williams PT, Wood PD, Krauss RM, et al. Does weight loss cause the exercise-induced increase in plasma high density lipoproteins? Atherosclerosis. 1983;47:173-85.
67. Wolf RN, Grundy SM. Effects of caloric restriction on plasma lipids and lipoproteins. Clin Res. 1980;28:55a.
68. Fong BS, Rodrigues PO, Salter AM, et al. Characterization of high density lipoprotein binding to human adipocyte plasma membranes. J Clin Invest. 1985;75:1804-12.
69. Despres JP, Fong BS, Julien P, Jimenez J, Angel A. Regional variation in HDL metabolism in human fat cells: effect of cell size. Am J Physiol. 1987;252:E654-9.
70. Schwartz RS. The independent effects of dietary weight loss and aerobic training on high density lipoproteins and apolipoprotein A-I concentrations in obese men. Metabolism. 1987;36:165-71.
71. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJ. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983;309:385-9.
72. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res. 1985;26:549-55.
73. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism. 1980; 29:1053-60.
74. Oram JF. Effects of high density lipoprotein subfractions on cholesterol homeostasis in human fibroblasts and arterial smooth muscle cells. Arteriosclerosis. 1983;3:420-32.
75. Khoo JC, Miller E, McLoughlin P, Steinberg D. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res. 1990;31:645-52.
76. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-7.
77. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991;87:536-44.
78. Gylling H, Vega GL, Grundy SM. Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res. 1992;33: 1527-39.
79. Ooi EM, Watts GF, Farvid MS, et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res. 2005;13:1008-16.
80. Brinton EA, Eisenberg S, Breslow JL. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest. 1989;84:262-9.
81. Brinton EA, Eisenberg S, Breslow JL. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates, J Clin Invest. 1990;85:144-51,
82. Brinton EA, Terry JG. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of lp A-I in postmenopausal women. Circulation. 1996;94 (Suppl):I-266.
83. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest. 1994;24:188-94.
84. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res. 2003;44: 1279-86.
85. Rashid S, Barrett PH, Uffelman KD, Watanabe T, Adeli K, Lewis GF. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol. 2002;22:483-7.
86. Rashid S, Uffelman K, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications. 2002;16:24-8.
87. Sasahara T, Yamashita T, Sviridov D, Fidge N, Nestel P. Altered properties of high density lipoprotein subfractions in obese subjects. J Lipid Res. 1997;38:600-11.
88. Krimbou L, Marcil M, Genest J. New insights into the biogenesis of human high-density lipoproteins. Curr Opin Lipidol. 2006;17:258-67.
89. Krimbou L, Hajj HH, Blain S, et al. Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. J Lipid Res. 2005;46:1668-77.
90. Francone OL, Gurakar A, Fielding C. Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem. 1989;264:7066-72.
91. Huang Y, von Eckardstein A, Assmann G. Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb. 1993;13:445-58.
92. Kaser S, Sandhofer A, Foger B, et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia. 2001;44:1111-7.
93. Sasahara T, Nestel P, Fidge N, Sviridov D. Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects, J Lipid Res. 1998;39: 544-54.
94. Miida T, Nakamura Y, Inano K, et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem. 1996;42:1992-5.
95. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369: 71-7.
96. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr. 1992;55 (1 Suppl):309S-13S.
97. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004; 4:CD004094.
98. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and metaanalysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437-46.
99. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 2000;1:127-39.
100. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-75.
101. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs. 2006;66:2109-19.
102. Wolf RN, Grundy SM. Influence of weight reduction on plasma lipoproteins in obese patients. Arteriosclerosis. 1983; 3:160-9.
103. Rossner S, Bjorvell H. Early and late effects of weight loss on lipoprotein metabolism in severe obesity. Atherosclerosis. 1987;64:125-30.
104. Seshadri P, Iqbal N, Stern L, et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med. 2004;117:398-405.
105. Wood PD, Stefanick ML, Dreon DM, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med. 1988;319:1173-9.
106. Williams PT, Krauss RM, Vranizan KM, Wood PD. Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation. 1990;81:1293-304.
107. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med. 1991;325:461-6.
108. Hayek T, Ito Y, Azrolan N, et al. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL-cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest. 1993;91:1665-71.
109. Williams PT. Lipoproteins and adiposity show improvement at substantially higher exercise levels than those currently recommended. American Heart Association Conference 66th Scientific Sessions. Atlanta, GA; November 8-11, 1993.
110. Leon AS, Conrad J, Hunninghake DB, Serfass R. Effects of a vigorous walking program on body composition, and carbohydrate and lipid metabolism of obese young men. Am J Clin Nutr. 1979;32:1776-87.
111. Lewis S, Haskell WL, Wood PD, Manoogian N, Bailey JE, Pereira MB. Effects of physical activity on weight reduction in obese middle-aged women. Am J Clin Nutr. 1976;29:151-6.
112. Thompson PD. What do muscles have to do with lipoproteins? Circulation. 1990;81:1428-30.
113. Brownell KD, Bachorik PS, Ayerle RS. Changes in plasma lipid and lipoprotein levels in men and women after a program of moderate exercise. Circulation. 1982;65:477-84.
114. Swank AM, Robertson RJ, Deitrich RW, Bates M. The effect of acute exercise on high density lipoprotein-cholesterol and the subfractions in females. Atherosclerosis. 1987;63:187-92.
115. Kantor MA, Cullinane EM, Herbert PN, Thompson PD. Acute increase in lipoprotein lipase following prolonged exercise. Metabolism. 1984;33:454-7.
116. Herbert PN, Bernier DN, Cullinane EM, Edelstein L, Kantor MA, Thompson PD. High-density lipoprotein metabolism in runners and sedentary men. JAMA. 1984;252: 1034-7.
117. Reisin E, Frohlich ED, Messerli FH, et al. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med. 1983;98:315-9.
118. Sopko G, Leon AS, Jacobs DR Jr, et al. The effects of exercise and weight loss on plasma lipids in young obese men. Metabolism. 1985;34:227-36.
119. Martin JE, Dubbert PM. Exercise applications and promotion in behavioral medicine: current status and future directions. J Consult Clin Psychol. 1982;50:1004-17.
120. Kiens B, Lithell H. Lipoprotein metabolism influenced by training-induced changes in human skeletal muscle. J Clin Invest. 1989;83:558-64.
121. Schwartz RS, Brunzell JD. Increase of adipose tissue lipoprotein lipase activity with weight loss. J Clin Invest. 1981;67:1425-30.
122. Mohanka M, Irwin M, Heckbert SR, et al. Serum lipoproteins in overweight/obese postmenopausal women: a one-year exercise trial. Med Sci Sports Exerc. 2006;38: 231-9.
123. Park SK, Park JH, Kwon YC, Kim HS, Yoon MS, Park HT. The effect of combined aerobic and resistance exercise training on abdominal fat in obese middle-aged women. J Physiol Anthropol Appl Human Sci. 2003;22:129-35.
124. Williams PT, Wood PD, Haskell WL, Vranizan K. The effects of running mileage and duration on plasma lipoprotein levels. JAMA. 1982;247:2674-9.
125. Williams PT. Weight set-point theory and the high-density lipoprotein concentrations of long-distance runners. Metabolism. 1990;39:460-7.
126. Thompson PD, Yurgalevitch SM, Flynn MM, et al. Effect of prolonged exercise training without weight loss on highdensity lipoprotein metabolism in overweight men. Metabolism. 1997;46:217-23.
127. Thompson PD, Cullinane EM, Sady SP, et al. Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training. Circulation. 1988; 78:25-34.
128. Rifkind BM. Gemfibrozil, lipids, and coronary risk. N Engl J Med. 1987;317:1279-81.
129. Wing RR, Jeffery RW. Outpatient treatments of obesity: a comparison of methodology and clinical results. Int J Obes Relat Metab Disord. 1979;3:261-79.